RNA discovery provides insight into bone diseases



A new study has revealed that the Cpeb4 protein may have a role in regulating osteoclast differentiation, a finding that could lead to the development of new therapeutic drugs for osteoporosis and rheumatoid arthritis.

In today’s aging societies, diseases affecting the bones and joints are becoming increasingly common. For example, in Japan alone, over 12 million people suffer from osteoporosis, a condition that severely weakens bones and makes them fragile.

In order to find effective treatments for these disorders, understanding the cellular processes involved in the maintenance of bone and joint tissue is an essential first step.

Osteoclasts are a particularly important type of cell involved in bone maintenance. These cells absorb old or damaged bone and digest it, allowing the body to reuse important materials like calcium and giving way to new bones.

Various bone diseases arise when osteoclasts do not fulfill their role properly, and scientists have been investigating the mechanisms that regulate the proliferation and differentiation of precursor cells into osteoclasts.

Researchers from Tokyo University of Science (TUS), led by Professor Tadayoshi Hayata, revealed in 2020 that the cytoplasmic polyadenylation element-binding protein 4 (Cpeb4) protein is essential in osteoclast differentiation.

They also discovered that this protein, which regulates the stability and translation of messenger RNA (mRNA) molecules, transported into specific structures within the nucleus of the cell when osteoclast differentiation was induced.

However, just how this relocation occurs and what Cpeb4 exactly does within these nuclear structures still remains a mystery.

Now, in a new study, Hayata and Yasuhiro Arasaki from TUS tackled these knowledge gaps, seeking to gain a better understanding of how the “life cycle” of mRNA, i.e. mRNA metabolism, is involved.

Cpeb4 proteins

The researchers introduced strategic modifications into Cpeb4 proteins and performed a series of experiments in cell cultures, finding that the localisation of Cpbe4 in the abovementioned nuclear bodies occurred owing to its ability to bind to RNA molecules.

Afterwards, seeking to understand the role of Cpeb4 in the nucleus, the researchers demonstrated that Cpeb4 co-localized with certain mRNA splicing factors. These proteins are involved in the process of mRNA splicing, which is a key step in mRNA metabolism. Put simply, it enables a cell to produce diverse mature mRNA molecules (and eventually proteins) from a single gene.

Through RNA sequencing and gene analysis in Cpeb4-depleted cells, they found that Cpeb4 alters the expression of multiple genes associated with splicing events in freshly differentiated osteoclasts.

Through further experiments, the researchers revealed that Cpeb4 only altered the splicing patterns of Id2 mRNA, an important protein known to regulate osteoclast differentiation and development.

Overall, this study sheds important light on the mechanisms that regulate osteoclast differentiation.

“Through this research, we were able to identify important factors involved in regulating mRNA splicing during the osteoclast differentiation process and obtained new knowledge regarding the control of mRNA splicing during osteoclast differentiation,” commented Professor Hayata.

While the contribution of Cpeb4 is smaller than that of RANKL, a signaling factor that induces osteoclast differentiation, targeting Cpeb4 may have the advantage of reducing the side effects of existing drugs as too much inhibition of osteoclast differentiation with RANKL inhibitory antibodies would halt bone remodeling.

Importantly, the results contribute to a more detailed understanding of how bones are maintained.

“Although we used cultured mouse cells in our study, there are also research reports that show a correlation between variations in the CPEB4 gene and bone density in humans,” added Hayata.

“We hope that our findings will help clarify the relationship between these two in the near future.”

Most importantly, the findings of the present study may prove to be a crucial stepping stone for advancing diagnostic techniques and treatments for bone and joint diseases.

GWAS analysis has reported a correlation between single nucleotide polymorphisms in introns of the CPEB4 gene region and the estimated bone density. Therefore, it is possible that CPEB4 expression and activity can be used as diagnostic criteria.

However, the researchers note that it is unclear whether Cpeb4 actually regulates bone metabolism in vivo. Therefore, clarification of the molecular basis of Cpeb4 in bone metabolism in mice would help to establish a therapeutic approach. Additionally, recent studies have reported that Cpeb4 is expressed in various cancer cells and contributes to cancer cell survival. In cancer, Cpeb4 contributes to mRNA stability, although splicing regulation may exist.

Hayata concluded: “The discovery of part of the mechanisms by which Cpeb4 controls osteoclast differentiation could lead to the elucidation of pathologies, including osteoporosis and rheumatoid arthritis, and ultimately become the foundation for the development of new therapeutic drugs.”

Click to comment


Exit mobile version